屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响

doi:10.3969/j.issn.1006-7795.2021.04.007

首都医科大学学报 ›› 2021, Vol. 42 ›› Issue (4): 547-552.doi: 10.3969/j.issn.1006-7795.2021.04.007

• 绝经、妇科内分泌与生育力保护 • 上一篇下一篇

屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响

杨瑜, 阮祥燕^*, 鞠蕊, 许新, 谷牧青, 程姣姣

首都医科大学附属北京妇产医院内分泌科, 北京 100026

收稿日期:2021-05-18 出版日期:2021-08-21 发布日期:2021-07-29
基金资助:
北京市医院管理局“登峰”计划专项(DFL20181401) 。

Effect of drospirenone/ethinylestradiol(Ⅱ) on serum anti-Müllerian hormone level in Chinese polycystic ovary syndrome women

Yang Yu, Ruan Xiangyan^*, Ju Rui, Xu Xin, Gu Muqing, Cheng Jiaojiao

Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China

Received:2021-05-18 Online:2021-08-21 Published:2021-07-29
Contact: * E-mail:ruanxiangyan@ccmu.edu.cn
Supported by:
Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20181401).

摘要/Abstract

摘要： 目的探讨屈螺酮炔雌醇Ⅱ对多囊卵巢综合征(polycystic ovary syndrome,PCOS)女性血清抗苗勒管激素(anti-Müllerian hormone,AMH)的影响。方法纳入2020年8月至2021年4月就诊于首都医科大学附属北京妇产医院内分泌科的PCOS患者74 例,比较屈螺酮炔雌醇Ⅱ治疗前后血清AMH浓度、性激素浓度及肝、肾功能指标的变化。并根据用药时间不同将患者分为3组:用药3个周期(A组,n=16)、4~6个周期(B组,n=28)、＞6个周期(C组,n=30)。结果口服屈螺酮炔雌醇Ⅱ后血清AMH的中位数(5.80 ng/mL)较服药前(9.17 ng/mL)显著降低(P＜0.001),服药前后AMH差值的中位数为2.53 ng/mL。A、B、C 3组患者用药前血清AMH的中位数分别为9.01、7.79、10.19 ng/mL,用药后血清AMH的中位数分别为7.01、5.06、6.70 ng/mL。3组患者用药后血清AMH均较用药前降低。结论服用屈螺酮炔雌醇Ⅱ 3个周期及以上可降低PCOS患者的血清AMH浓度。

关键词: 多囊卵巢综合征, 抗苗勒管激素, 屈螺酮炔雌醇Ⅱ

Abstract: Objective To evaluate the effect of drospirenone/ethinylestradiol(Ⅱ)(pills for contraception and use for the treatment of hyperandrogenenism) on serum anti-Müllerian hormone(AMH) level in Chinese polycystic ovary syndrome (PCOS) patients. Methods Totally 74 PCOS patients who were admitted to the Department of Gynecological Endocrinology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,China from August 2020 to April 2021 were enrolled in this study. The serum AMH,sex hormones,liver and kidney function were measured before and after the use of drospirenone/ethinylestradiol tablets (Ⅱ). The patients were divided into three groups according to the duration of taking pills: group A(n=16) for 3 cycles,group B (n=28) for 4-6 cycles and group C(n=30) for more than 6 cycles. Results The median serum AMH level after treatment (5.80 ng/mL) was significant lower than that before treatment (9.17 ng/mL) (P＜0.001). The median change of AMH level before and after the use of drospirenone/ethinylestradiol tablets(Ⅱ) was 2.53 ng/mL. The median serum AMH were 9.01 ng/mL,7.79 ng/mL and 10.19 ng/mL before treatment and 7.01 ng/mL,5.06 ng/mL and 6.70 ng/mL after treatment in group A,group B and group C,respectively. The serum AMH was decreased after treatment in all groups. Conclusion Taking drospirenone and ethinylestradiol II for 3 cycles or more could reduce the serum AMH level in PCOS patients.

Key words: polycystic ovary syndrome, anti-Müllerian hormone, drospirenone/ethinylestradiol(Ⅱ)

中图分类号:

R711.75

杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.

Yang Yu, Ruan Xiangyan, Ju Rui, Xu Xin, Gu Muqing, Cheng Jiaojiao. Effect of drospirenone/ethinylestradiol(Ⅱ) on serum anti-Müllerian hormone level in Chinese polycystic ovary syndrome women[J]. Journal of Capital Medical University, 2021, 42(4): 547-552.

参考文献

[1] Lizneva D,Suturina L,Walker W,et al. Criteria,prevalence,and phenotypes of polycystic ovary syndrome[J]. Fertil Steril,2016,106(1):6-15.
[2] 中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志,2018,53(1):2-6.
[3] di Clemente N,Racine C,Pierre A,et al. Anti-Mullerian hormone in female reproduction[J]. Endocr Rev,2021, Epub ahead of print.
[4] 王虎生,阮祥燕,李雪,等. 抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值[J]. 首都医科大学学报,2017,38(4):492-497.
[5] Hsu J Y,James K E,Bormann C L,et al. Müllerian-inhibiting substance/anti-müllerian hormone as a predictor of preterm birth in polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2018,103(11):4187-4196.
[6] Hu K,Liu F,Xu H,et al. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome[J]. Fertil Steril,2020,113(2):444-452.
[7] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril,2004,81(1):19-25.
[8] Lie F S,Visser J A,Welt C K,et al. Serum anti-Müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab,2012,97(12):4650-4655.
[9] Orisaka M,Miyazaki Y,Shirafuji A,et al. The role of pituitary gonadotropins and intraovarian regulators in follicle development: A mini-review[J]. Reprod Med Biol,2021,20(2):169-175.
[10] 邱玲,李丹丹,程歆琦. 抗缪勒管激素的临床应用[J]. 协和医学杂志,2017,8(Z2):229-234.
[11] 袁莹莹,宋晓霞,赵君利,等. 不同年龄组PCOS患者AMH水平及助孕结局分析[J]. 宁夏医科大学学报,2021,43(3):239-243.
[12] 万德花,程强军. 不同年龄段PCOS患者血液AMH水平的临床研究[J]. 生殖医学杂志,2018,27(8):787-789.
[13] Amer S A K S,James C,Al-Hussaini T K,et al. Assessment of circulating anti-müllerian hormone in women using hormonal contraception: a systematic review[J]. J Women's Health,2020,29(1):100-110.
[14] 宋颖,李蓉. 多囊卵巢综合征中国诊疗指南解读[J]. 实用妇产科杂志,2018,34(10):737-741.
[15] 杨荔凡,张艳. 屈螺酮炔雌醇复合片对多囊卵巢综合征患者的有效性探讨[J]. 中外女性健康研究,2019(23):85-101.
[16] Li Y,Ruan X,Wang H,et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J]. Fertil Steril,2018,109(4):720-727.
[17] Christ J P,Gunning M N,Meun C,et al. Pre-conception characteristics predict obstetrical and neonatal outcomes in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab,2019,104(3):809-818.

屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响

Effect of drospirenone/ethinylestradiol(Ⅱ) on serum anti-Müllerian hormone level in Chinese polycystic ovary syndrome women

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[2]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[3]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[4]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[5]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[6]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[7]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[8]	豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.
[9]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[10]	阮祥燕, 张露平, 代荫梅, 王虎生, 金凤羽, 谷牧青, 程姣姣, 鞠蕊, 闵敏, Thomas Roemer. 门诊微型宫腔镜检查在不孕症患者中的临床应用[J]. 首都医科大学学报, 2019, 40(4): 549-553.
[11]	谷牧青, 李扬璐, 程姣姣, 王虎生, 阮祥燕, 贾婵维. 达英-35对多囊卵巢综合征患者代谢与性激素的影响[J]. 首都医科大学学报, 2019, 40(4): 560-565.
[12]	闵敏, 阮祥燕, 赵越, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, 张露平, 王月姣, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(4): 572-577.
[13]	杜娟, 阮祥燕, Alfred O. Mueck. 口服避孕药对多囊卵巢综合征患者性功能的影响[J]. 首都医科大学学报, 2018, 39(4): 499-504.
[14]	金婧, 阮祥燕, 华琳, 李杨璐, 王利娟, 王虎生, 赵越, Alfred O. Mueck. 多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J]. 首都医科大学学报, 2018, 39(4): 505-511.
[15]	王虎生, 阮祥燕, 李扬璐, 程姣姣, 谷牧青, 杜娟, 金凤羽, Alfred O. Mueck. 丙二醛、视黄醇与多囊卵巢综合征发病机制关系的探索[J]. 首都医科大学学报, 2018, 39(4): 512-516.